Background Severe trauma represents a major global public health burden and the
management of post-traumatic bleeding continues to challenge healthcare systems around …

Globally, approximately 70 million people sustain traumatic brain injury each year and this
can have significant physical, psychosocial and economic consequences for patients, their …

Introduction Over the last decade, tranexamic acid (TXA) has been incorporated into
treatment algorithms for a multitude of emergent conditions and the evidence surrounding its …

A focused assessment with sonography in trauma examination is positive for free fluid in the
right upper quadrant. There is no evidence of pneumothorax on ultrasound. Her pelvis is …

BACKGROUND Impaired coagulation is associated with elevated risk of mortality in trauma
patients. Prior studies have demonstrated increased mortality in patients with …

Background Thromboelastography is a viscoelastic test with multiple potential advantages
over conventional coagulation tests in various disease states. Thromboelastography rapidly …

BACKGROUND Improved outcomes with early tranexamic acid (TXA) following trauma
hemorrhagic shock (T/HS) may be related to its antifibrinolytic, as well as anti-inflammatory …

Uncontrolled haemorrhage remains the leading cause of early mortality in major trauma
accounting for 30e40% of all trauma deaths. Approximately 50% of trauma deaths that are …

Background: Tranexamic acid (TXA) is an antifibrinolytic used for prophylaxis and treatment
of acute bleeding. Although fixed dosing is often used in practice, weight-based dosing is …

BACKGROUND Brain specific biomarkers such as glial fibrillary acidic protein (GFAP),
ubiquitin C-terminal hydrolase L1 (UCH-L1), and microtubule-associated protein-2 (MAP-2) …